+ All Categories
Home > Documents > Alkem Corporate PPT

Alkem Corporate PPT

Date post: 24-Nov-2014
Author: dewanshu5457
View: 171 times
Download: 5 times
Share this document with a friend
Embed Size (px)
Popular Tags:
of 54 /54
Making Positive Difference To Lives Across The Globe ALKEM LABORATORIES


Making Positive Difference To Lives Across The Globe


To achieve value driven leadership in Indian Health Care Industry and beyond through Quality that is infinite Service that cares Hardwork that endures.


To be one of the

Top 3 Companiesin India and also be a successful global Company through innovations and strategic alliances

Visionary Founder and Chairman

Managing Director

4 Decades Of Giant Strides

The Pharma Major since 1973Turnover Rs 1,293 cr

Ranked No. 5 in the Indian Pharma Industry

Enjoys high respect from Medical profession & trade in India

Reputed for building mega brands

4 Decades Of Giant Strides

Buoyant organic growth due to excellent marketing and sales

On the path of rapid globalisation

Products exported to 60 countries

moving ahead to become one of the top 3 Indian companies

Sales Break Up Acute And Chronic Segments

7%Chronic Segment

93%Acute Segment

Total Sales Turnover

Year Total Sales

2005-06 169

2006-07 226

2007-08 239

2008-09 272



Val in Mn US$

2009 - 10 Domestic SalesSBUs Main Division Bergen Ulticare Pentacare Generic CytomedValue(in Crs)

692.95 150.91 95.73 13.79 111.08 21.72 27.75 15.05 29.70 6.82 6.34 121 Total (App.) 1293

MedivaDerma Care Alkem Pharma

Alkem Health FoodsAlkem Institution Exports

Top 10 Domestic Company


Growth Rate of Company Mankind Pfizer Sun ALKEM Zydus Cadila Aristo Cipla Glaxo Group Lupin Ranbaxy 37% 33% 26% 23% 23% 20% 18 % 17% 16% 11%

ALKEM -A Brand Building CompanyTaxim (Cefotaxime) a flagship brand is among the top 15 brands of Indian Pharmaceutical Industry

11 other brands in the list of top 300 mega brands

No. 1 in Cephalosporins

Front runners in Co-AmoxyClav and Quinolone segments

Brands In Top 300 Of Indian Pharma MarketRankTaxim (Cefotaxime) Taxim-O (Cefixime) Clavam (Co-Amoxyclav) Pan Sumo ( NSAID) Gemcal (Calcitrol) A TO Z (Multi Vitamin/Anti-oxidants) Xone (Ceftriaxone) Pan - D Ondem Hemfer (Hematinic)

Val in Cr.

11 15 30 74 82 83 94 117 145 168 232

131.72 105.88 87.27 57.63 51.94 51.89 45.53 40.82 36.84 32.92 27.29

ORG Mat May 2010

ALKEM in Cephalosporins

Company Market ALKEM Aristo Ranbaxy


Value (in Cr.)

% MS

% Gr

3185.96 1 2 3 396.85 271.72 246.63 12.5 8.5 7.7

17 7 25 17

ORG Mat May 2010

ALKEM in Co-AmoxyClav

Company Market Glaxo Smithkline ALKEM Mankind


Value (in Cr.)

% MS

% Gr

634.07 1 2 3 154.21 93.95 70.27 24.43 14.8 11

35 31 33 20

ORG Mat May 2010

ALKEM in Quinolones

Company Market Ranbaxy Cipla Mankind ALKEM


Value (in Cr.)

% MS

% Gr.

972.71 1 2 3 8 191.26 146.58 72.02 31.61 19.7 15.11 7.4 3.2

4 14 7 14 26

ORG Mat May 2010

Firsts From Alkem

First Indian Company To Develop, Manufacture & Market These Products In India Anaestrazole Cefotaxime + Sulbactam Satranidazole Ceftriaxone + Tazobactam Cefixime + Clavulanic Acid

First Company To Market These Products In India MEROPENAM CEFEPIME

Important New Products Launched Cefixime + Clavulanic Acid Ceftriaxone + Tazobactam Pantaprazole + Itopride Aceclofenac Range Rabeprazole + Diclofenac Meropenam Cefipime Piperacillin + Tazobactam Cefotaxime + Sulbactam Cefprozil Gatifloxacin Cefpodoxime Proxetil Rabeprazole Rabeprazole + Domperidone Sodium Feredetate Donepezil

Important New Products Launched Levo Cetirizine Aripiprazole Bicalutamide Natural Micronised Progesterone Anaestrazole Paclitaxel

Atorvastatin + Ezetemibe Pioglitazone + Metformin Metformin SR Glimepiride EsCitalopram Mirtazapine Quetiapine Nebivolol

NATURAL PRODUCTS Pycnogenol INTERESTING NUTRACEUTICAL PRODUCTS Protein Diskettes Meal Replacer Bars Nutraceutical soups

Our Core Strengths

Focussed SBUs

Technical Expertise




Focussed SBUS

Focused SBUsMain Pharma Division Ulticare Bergen

Pentacare Mediva Cytomed Derma Care

Therapy Representation Of SBUs

Main Pharma AntiAnti-infective Gastroenterology Gynecology Pediatric Surgery Nutraceuticals Nsaids Urology

Ulticare AntiAnti-infective Nutraceuticals AntiAnti-tuberculosis Special Focus - Paediatrics


AntiAnti-infective Orthopedics Nutraceuticals Dermatology

Therapy Representation Of SBUs



AntiAnti-parkinson's AntiAnti-depressants AntiAnti-psychotics

Cardio Vascular & Anti Diabetic Range


AntiAnti-cancer Anti retrovirals

Anxiolytics AntiAnti-epileptics AntiAnti-alzheimer's

DermacareSkin Care Division

Diversified Business

Alkem Health Foods :

Jeevan prash a tasty, Low Calorie & sugar free chyawanprash Blocal Low Calorie Sweetner Tammy : Salt Substitute, Fat Substitutes and Sucralose based products Jams, Cookies, Jelly, Juices & cakes (Calorie Conscious and Diabetics), Cholesterol free edible Oil.

Technical Expertise

The Research And Development Centre Active In Almost All Facets Of The Business

R&D centre at Mumbai approved by DSIR

Formulation development for domestic market Formulation development for MAA/ANDA program Process development group for APIs and nutraceuticals Fully equipped modern state-of-the-art labs Sophisticated information services

State-of-the Art Manufacturing Committed To International Quality Compliance

7 World class manufacturing facilities 2000 Million units of Tablets per annum 200 Million units of Capsules p.a 500 Million units of Injectable p.a 60 Million units of Liquids p.a 600 Million units of dry syrups p.a 30 Mn Units of I.V. infusions p.a.

Manufacturing Locations

Daman Amailya and Kachigam Plant Gujrat -Mandava and Ankaleshwar Plant Himachal Pradesh Baddi Sikkim - Rangpo

Contract Research Organization( Phoenix Bio-Pharma Research Centre )

Conforming to International standards Bio- equivalence studies Drug Metabolism Pharmacokinetics Method Development / Method Validation etc. Post Marketing Surveillance Independent Ethics Committee comprising of well known personalities eg. Dr. H.P. Tipnis

Low cost for studies as compared to the west


ALKEM Our People

Over 6000 employees Cohesive team of professionals with a proven track record andcomplementary skills

Well Trained, Competent and Dedicated field force across the country Creative & Vibrant strategic Marketing Team with experience of building mega brands Competent pool of Scientists, Pharmacists & Technologists

Our Values Honesty and Integrity Respect/care & concern for people Customer Orientation Commitment to Quality Learning Organization Dedication and Commitment Trust Teamwork Openness and Transparency Discipline Result Oriented


Selling & Distribution Channels

Depots: 24 C&F: 4 Warehouse : 4 3000 Field Force spanning the entire country 1,40,000 retailer coverage 3,65,000 Doctor coverage ( 40 % of universe )


Financial Strength Negligible Debt; Major Project Cost and Expansion Programs metout of Retained Earnings

Low Borrowing Cost, Interest Cost progressively becoming nil, NetIncome generated on the Interest Front

Owns substantial Properties and Tangible Assets Tax Planning, Profit Tax free subject to MAT Liquidity Accumulated Cash Reserves and Surplus Surplus available for Expansion, R&D and M&A Activity

International Footprint

Key Attributes

Excellent growth in exports in last 3 years

Currently exports to more than 60 countries

Exports to regulated markets in Europe including UK

Strategic Approach

1. Marketing through agent network in Unregulated andSemiregulated markets

2. Regulated Markets

Toll manufacture for large generic companies in Highly regulated markets like Europe, South Africa, Australia & USA Own European filings & US ANDAs Strategic Alliances , Acquisitions & JVs

Strategic Alliance

Contract manufacturing for generic companies in regulated European Market

Alliance with other European and American generic major`s in process

Tie-up for innovative nutraceuticals and food products in process

REGULATORY APPROVALSCephalosporin Block Oral & Injectable (Daman) Approved by UK MHRA ( orals & injectable ) Approved by MCC, south Africa ( orals & injectable ) Approved by ANVISA, brazil (injectable)

Beta lactam block (daman) Approved by ANVISA brazil (injectables ) Successfully inspected by UKMHRA ( Oral & Injectable) approval expected shortly General block facility (daman) Approved by USFDA & UKMHRA( ORAL ) and also approved by ANVISA Brazil

USFDA Process for all the three Blocks has been initialized and completed

Our New Ventures


Developed a cost effective , environment friendly, patent non infringing process Confirms to USP-NF specifications Certified by CFTRI & BAJAJ centre Dedicated facility based on regulated market requirements Capacity : 10 tonnes/month

Foray Into Biotechnology


Looking Ahead

MAAs in European Market ANDAs in USA Contract manufacturing for generic companies in regulated EuropeanMarket

In licensing arrangement for marketing PATENTED molecules in India Strategic alliances, Acquisitions & JVs Backward integration to API manufacturing. cGMP lab & pilot plant; futuristic contract research business opportunities Identifying and Contract research business opportunities

Why you should work with Alkem

We are Growing organization Fast Career Growth Performance Driven Organization. We are growing at the rate of 23 % per annum as compared to the Industrygrowth rate of 17 %.

Compare to all top rank companies in domestic we are growing at higherrate.

Incentive driven compensation structure. Believe in Fun at work place.

Web Site

www. alkemlabs.com